Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

9.700 +0.090 (+0.94%)
Streaming Delayed Price Updated: 2:32 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Niagen Bioscience, Inc. - Common Stock

Breaking Down Niagen Bioscience: 4 Analysts Share Their Views
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Niagen NAGE Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
What's Next: Niagen Bioscience's Earnings Preview
 
Via Benzinga
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook
From Niagen Bioscience, Inc.
Via Business Wire
Examining the Future: Niagen Bioscience's Earnings Outlook
 
Via Benzinga
Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Participate at the Roth 15th Annual London Conference
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Participate in the BIO 2025 International Convention
From Niagen Bioscience, Inc
Via Business Wire
What 4 Analyst Ratings Have To Say About Niagen Bioscience
 
Via Benzinga
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
From Niagen Bioscience, Inc
Via Business Wire
This Sandisk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs
From Niagen Bioscience, Inc
Via Business Wire
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
From Niagen Bioscience, Inc
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.